Amyotrophic Lateral Sclerosis

A Global Strategic Business Report

MCP10278

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

903

EXECUTIVE POOL

5850

PRICE

181

EXPERT INPUTS

23

COMPANIES

123

DATA TABLES

183

PAGES

9

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (555)

48

CXO

60

VICE PRESIDENT

180

DIRECTOR

104

MANAGER

163

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Amyotrophic Lateral Sclerosis Market to Reach US$3.6 Billion by 2030

The global market for Amyotrophic Lateral Sclerosis estimated at US$1.2 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 19.4% over the analysis period 2024-2030.

The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR

The Amyotrophic Lateral Sclerosis market in the U.S. is estimated at US$345.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$534.5 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.1% and 16.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Global Amyotrophic Lateral Sclerosis Market - Key Trends and Drivers Summarized

What is Amyotrophic Lateral Sclerosis (ALS) and How Does It Impact the Body?

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. This condition leads to the gradual degeneration and death of motor neurons, which are essential for controlling voluntary muscles. As these neurons deteriorate, patients experience muscle weakness, twitching, and eventually, the loss of the ability to initiate and control muscle movement. This leads to severe physical impairments, including difficulties in speaking, swallowing, and breathing. Despite the varying progression rates among individuals, ALS invariably leads to paralysis and is ultimately fatal, with the majority of patients succumbing to respiratory failure within three to five years from the onset of symptoms. Understanding the nature of ALS is crucial for developing effective treatments and providing comprehensive care for those affected.

How Are Research and Treatments Evolving for ALS?

Research into ALS is rapidly advancing, with numerous studies focusing on understanding its underlying mechanisms and developing potential treatments. Genetic research has identified several gene mutations associated with familial ALS, providing insights into its hereditary forms and opening avenues for targeted therapies. The development of biomarkers is another critical area, aiming to improve diagnosis, monitor disease progression, and evaluate treatment efficacy. Currently, only a few medications, such as Riluzole and Edaravone, are approved for ALS, offering modest benefits in slowing disease progression. However, ongoing clinical trials are exploring various approaches, including gene therapy, stem cell therapy, and the use of neuroprotective agents. Advances in technology are also facilitating innovative treatment modalities, such as brain-computer interfaces that help ALS patients communicate and control devices using their brain signals. These evolving research and treatment strategies are essential for improving the quality of life and prognosis for ALS patients.

What Challenges and Opportunities Exist in Managing ALS?

Managing ALS presents significant challenges, given the rapid progression and severe impact of the disease. Multidisciplinary care, involving neurologists, physical therapists, speech therapists, and other healthcare professionals, is vital for addressing the complex needs of ALS patients. Access to specialized care centers and support services can enhance disease management, but geographical and financial barriers often limit this access. Additionally, the emotional and psychological burden on patients and caregivers is substantial, necessitating comprehensive support systems. Despite these challenges, there are opportunities for improving care through technological innovations, such as telemedicine and assistive devices, which can provide remote support and enhance patient independence. Advocacy and awareness initiatives are also crucial for securing funding for research and improving public understanding of ALS, ultimately contributing to better patient outcomes and support networks.

What is Driving Market Growth for ALS Treatments?

The growth in the Amyotrophic Lateral Sclerosis (ALS) market is driven by several factors, including advancements in medical research, increasing awareness of the disease, and the development of innovative treatment approaches. Technological advancements, such as the identification of genetic markers and the use of advanced imaging techniques, are enhancing the understanding and diagnosis of ALS. The rise in funding for ALS research from both governmental and non-governmental organizations is spurring the development of new therapies and clinical trials. The growing demand for effective treatments is also driven by an aging population, as the incidence of ALS increases with age. Additionally, the expansion of patient advocacy groups and awareness campaigns is leading to earlier diagnosis and better access to care, further propelling market growth. Pharmaceutical companies are increasingly investing in the development of novel therapies, including gene therapies and neuroprotective agents, which hold promise for altering the course of the disease. These factors collectively are sustaining the momentum in the ALS treatment market, offering hope for improved management and potential cures in the future.

SCOPE OF STUDY

The report analyzes the Amyotrophic Lateral Sclerosis market by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Amyotrophic Lateral Sclerosis).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

AB Science SA; Apotex, Inc.; Aquestive; Biogen, Inc.; Brainstorm Cell Therapeutics Inc.; Cytokinetics, Inc.; F. Hoffmann-La Roche AG; Genervon Biopharmaceuticals LLC; Ionis Pharmaceuticals, Inc.; Kringle Pharma Inc.; Mitsubishi Tanabe Pharma Corporation; Neuralstem, Inc.; Orion Corporation; Orphazyme A/S; Sanofi SA; Treeway BV; Valeant Pharmaceuticals International, Inc.; ViroMed Co., Ltd.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

Global Economic Update

Amyotrophic Lateral Sclerosis – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 23 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence of ALS Drives Adoption of Multidisciplinary Care Approaches

Increasing Genetic Research Throws the Spotlight On ALS Understanding

Advancements in Biomarkers Propel Growth in ALS Diagnosis and Treatment

Development of Gene Therapies Expands Addressable Market Opportunity

Innovations in Stem Cell Research Strengthen Business Case for ALS Treatments

Innovations in Brain-Computer Interfaces Enhance Patient Communication

Advances in Neuroprotective Agents Accelerate Demand for New ALS Therapies

Aging Population Expands Market Opportunity for ALS Treatments

Advances in Imaging Techniques Propel Growth in ALS Diagnostic Accuracy

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

World Amyotrophic Lateral Sclerosis Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

UNITED STATES

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

CANADA

Canada Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

JAPAN

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

CHINA

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

EUROPE

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

FRANCE

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

GERMANY

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

ITALY

Italy Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UNITED KINGDOM

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

ASIA-PACIFIC

Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
AB Science SA	%
Aquinnah Pharmaceuticals	%
BioArctic AB	%
Biogen, Inc.	%
BrainEver	%
BrainStorm Cell Limited	%
Clene Nanomedicine	%
Helixmith Co., Ltd.	%
Immunity Pharma	%
Ionis Pharmaceuticals, Inc.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll